PILOT-STUDY ON THE EFFICACY OF INTRAVENOUS NATURAL INTERFERON-BETA THERAPY IN ITALIAN PATIENTS WITH CHRONIC HEPATITIS-C AND RELATION TO THE HCV GENOTYPE

被引：9

作者：

CHEMELLO, L ^{[1
]}

SILVESTRI, E ^{[1
]}

CAVALLETTO, L ^{[1
]}

BERNARDINELLO, E ^{[1
]}

PONTISSO, P ^{[1
]}

BELUSSI, F ^{[1
]}

ALBERTI, A ^{[1
]}

机构：

[1] DEPT INFECT DIS,VENICE,ITALY

来源：

INTERNATIONAL HEPATOLOGY COMMUNICATIONS | 1995年 / 3卷 / 05期

关键词：

NATURAL INTERFERON-BETA THERAPY; CHRONIC HEPATITIS C; HCV GENOTYPES;

D O I：

10.1016/0928-4346(94)00185-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Eight Italian patients with chronic hepatitis C were treated intravenously with natural beta-interferon (beta-IFN) to assess primary biochemical and virological response and also to investigate the relation to the genotype of infecting HCV. Each patient received 6 MU of beta-IFN daily for 6 days a week for a period of 2 months. Five patients (62.5%) showed complete normalization of alanineaminotransferase (ALT) and 6 cases (including all 5 with normal ALT) became HCV-RNA negative. ALT normalization occurred within 7-40 days of therapy. Seven patients were infected by HCV-1b and 4 (58%) of them became HCV-RNA negative with normal ALT at the end of therapy while one patient, infected by HCV-2a, became HCV-RNA negative but maintained elevated ALT values. Six months after cessation of beta-IFN all 8 patients were HCV-RNA positive in serum but 3 of them had normal ALT, including one case in whom normalization had occurred after therapy. These results indicate that HCV activity, including that of HCV-1b can be efficiently suppressed by intravenous beta-IFN therapy in Caucasian patients with chronic hepatitis C, as previously described in similar cases in Japan. The rate of sustained biochemical and virologic response was, however, lower in our patients compared to what has been described previously, suggesting that further studies are needed to define the optimum regimen to achieve eradication of HCV infection.

引用

页码：237 / 243

页数：7

共 12 条

[1]

Choo, Weiner, Overby, Et al., Hepatitis C virus: The major causative agent of viral Non-A, Non-B hepatitis, Br Med Bull, 46, pp. 423-441, (1990)

[2]

Koretz, Stone, Mousa, Et al., The NANB post- transfusion hepatitis. A decade later, Gastroenterology, 88, pp. 1251-1254, (1985)

[3]

Di Bisceglie, Martin, Kassianides, Et al., Recombinant interferon-alpha therapy for chronic hepatitis C, N Engl J Med, 321, pp. 1506-1510, (1989)

[4]

Davis, Balard, Schiff, Et al., Treatment of chronic hepatitis C with recombinant interferon alfa, N Engl J Med, 298, pp. 80-82, (1989)

[5]

Alberti, Chemello, Bonetti, Et al., Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C, Journal of Hepatology, 17, 3, pp. S123-S126, (1992)

[6]

Shindo, Di Bisceglie, Cheung, Et al., Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C, Ann Intern Med, 115, pp. 700-704, (1991)

[7]

Ohnishi, Nomura, Nakano, Et al., Interferon therapy for acute post-transfusion Non-A, Non-B heptitis: Response with respect to anti-hepatitis C virus antibody status, Am J Gastroenterol, 86, pp. 1041-1049, (1991)

[8]

Kobayashi, Watanabe, Konishi, Et al., Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta, Hepatology, 18, pp. 1319-1325, (1993)

[9]

Yoshioka, Kakumu, Wakita, Et al., Detection of hepatitis C virus by polymerase chain reaction and response to alpha-interferon therapy: Relationship to genotypes of hepatitis C virus, Hepatology, 16, pp. 293-299, (1992)

[10]

Tisminetzky, Gerotto, Pontisso, Et al., Genotypes of hepatitis C virus in Italian patients with chronic hepatitis C, Int Hepatol Commun, 2, 2, pp. 105-110, (1994)

← 1 2 →